SEC Company Response from Inhibitor Therapeutics, Inc. (INTI) (CIK 0001042418) (INTI) — Aug 6, 2015
Inhibitor Therapeutics, Inc. (INTI) (CIK 0001042418)
Date: Aug. 6, 2015 · CIK: 0001042418 · Accession: 0001193125-15-280695
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-198800
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attn: Jeffrey P. Riedler Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-198800
Dear Mr. Riedler:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, HedgePath Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. on Monday, August 10, 2015, or as soon as thereafter practicable.
Please note that we acknowledge the following:
•
should the Securities and Exchange Commission (the “Commission”) or the staff (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
/s/ Nicholas J. Virca
Show Raw Text
CORRESP 1 filename1.htm Correspondence HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 August 6, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-198800 Dear Mr. Riedler: Pursuant to Rule 461 under the Securities Act of 1933, as amended, HedgePath Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. on Monday, August 10, 2015, or as soon as thereafter practicable. Please note that we acknowledge the following: • should the Securities and Exchange Commission (the “Commission”) or the staff (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, /s/ Nicholas J. Virca Nicholas J. Virca President and Chief Executive Officer